biostudies-literatureYamamoto Ythe Ministry of Education, Culture, Sports, Science and Technology and the Japan Society for Promotion of Science (KAKENHI)488https://www.ebi.ac.uk/biostudies/studies/S-EPMC12897004biostudies-literatureUnknown18(3)<h4>Background/objectives</h4>The role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis.<h4>Methods</h4>We retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21-30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared.<h4>ResulCancersValidation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching.PMC1289700421K09161 and 25K12326Tamura RMorimoto YMiyake KSasaki HYamamoto YTanaka TTakei JMurayama YTomoto KAkasaki YHasegawa YTeshigawara AfalseValidation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching.<h4>Background/objectives</h4>The role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis.<h4>Methods</h4>We retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21-30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared.<h4>Resul2026-01-01T00:00:00Z2026 Feb2026-07-08T03:11:35.582Z2026-07-08T03:08:37.778ZS-EPMC128970044168196010.3390/cancers18030488